Evidence suggests that high-molecular-weight IGF-2, secreted by non-islet cell tumors of mesenchymal origin, interacts with insulin and IGF-1 receptors, as well as binding proteins, to induce the expression of hexokinase and other glycolytic enzymes. The gene discussed is IGF2; the disease is pancreatic neuroendocrine tumor.